Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1525
Full metadata record
DC FieldValueLanguage
dc.contributorPillay, Monishaen_US
dc.contributorShaw, Michaelen_US
dc.contributorVincent, C.en_US
dc.contributorFrawley, Natashaen_US
dc.date.accessioned2020-06-03T03:39:13Z-
dc.date.available2020-06-03T03:39:13Z-
dc.date.issued2019-
dc.identifier.govdoc01482en_US
dc.identifier.urihttp://hdl.handle.net/11054/1525-
dc.description.abstractBackground: Remifentanil is a potent short acting opioid which is rapidly metabolised by mother and fetus. Despite positive data published in a meta‐analysis, remifentanil is not used widely in Victoria for labour analgesia. Ballarat Health Services has approximately 1,400 births per annum with Remifentanil being offered as patient controlled analgesia to women in labour. The aim of this retrospective cohort study was to determine the efficacy, patient satisfaction and maternal and neonatal adverse effects profile of remifentanil. Methods: A retrospective cohort study was conducted over a period of 6 months, from January to June 2018 of all births at a single regional centre. Subjects were identified via routinely collected birth data. Dose of Remifentanil was 20mcg/mL. Four parameters had data collected including maternal demographics, labour, analgesia and neonatal outcomes. Results: Of 641 births, 45 patients used remifentanil. Patients were 19‐ 40 years old with BMIs of 20‐38 and generally over 37 weeks gestation. 2 patients required Remifentanil for management of a FDIU. 17 patients presented in spontaneous labour with 18 having inductions mainly due to high BMI and GDM. 67% of patient used Nitrous prior to Remifentanil with 18% of patients requiring an epidural. 7% required an instrumental delivery subsequent to remifentanyl. 100% of neonates had a 5‐minute APGAR >6 with 7% requiring a SCN admission and 2% of neonates requiring resuscitation at birth. Conclusions: This audit indicates that the use of Remifentanil in labour was associated with a high subsequent vaginal delivery rate and no significant adverse neonatal outcomes as a direct result.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2020-06-03T03:38:45Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2020-06-03T03:39:13Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2020-06-03T03:39:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.titleRemifentanil in labour: retrospective audit of a single regional centre’s outcomes.en_US
dc.typeConferenceen_US
dc.type.specifiedPaperen_US
dc.bibliographicCitation.conferencedateMarch 17-20en_US
dc.bibliographicCitation.conferencenamePSANZ2019 – Perinatal Society of Australia and New Zealand Annual Scientific Meetingen_US
dc.bibliographicCitation.conferenceplaceGold Coasten_US
dc.subject.healththesaurusLABOURen_US
dc.subject.healththesaurusREMIFENTANILen_US
dc.subject.healththesaurusPAIN MANAGEMENTen_US
dc.subject.healththesaurusANALGESIAen_US
dc.subject.healththesaurusINTRAPARTUM PERIODen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.